Clinical trial registry record

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 2, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05463133
Last registry update
October 2, 2026
Status
Recruiting
Phase
Phase 1, Phase 2
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment
50
Countries
United States
Match confidence
62%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NA · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
50
Population
ALL · 4 Years to 65 Years
Duration
2022-07-08 to 2032-12-31
Intervention
Sirolimus; Cyclophosphamide; Alemtuzumab; Busulfan; Pheripheral blood stem cells; Emapalumab-Izsg; Tociluzumab; Total Body Irradiation
Comparator
Arm 1 / Group 1 Standard Risk
Outcomes measured
Overall Survival — 1 years post-transplant.; To assess the infection rates in the setting of Alemtuzumab (Campath-1H) and post-transplant cyclophosphamide with the…; To assess kinetics of engraftment — Day +14, +30, +60, +100, 6 month and 1 year post transplant; Improve eligibility for allogeneic transplantation. — Eligibility determination for protocol enrollment; Engraftment without GvHD — Day 100, 6 months, and/or 1 year post BMT; Decreased engraftment syndrome. — 30 days post transplant.
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 62% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 62%Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON